Menu Search
Equities

Avanos Medical Inc

8HH:MUN

Avanos Medical Inc

Actions
  • Price (EUR)17.40
  • Today's Change0.10 / 0.58%
  • Shares traded0.00
  • 1 Year change-35.56%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 07:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avanos Medical, Inc. is a medical device company, which is focused on delivering solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Company’s acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The Company's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products.

  • Revenue in USD (TTM)673.30m
  • Net income in USD-9.90m
  • Incorporated2014
  • Employees3.77k
  • Location
    Avanos Medical Inc5405 Windward Parkway, Suite 100 SouthALPHARETTA 30004United StatesUSA
  • Phone+1 (678) 425-9273
  • Fax+1 (302) 636-5454
  • Websitehttps://avanos.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AVNS:NYQ since
announced		Transaction
value
Diros Technology IncDeal completed19 Jun 202319 Jun 2023Deal completed-23.01%--
Data delayed at least 15 minutes, as of May 02 2024 21:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.